Literature DB >> 17075331

The role of new therapies for severe community-acquired pneumonia.

Marcos I Restrepo1, Antonio Anzueto.   

Abstract

PURPOSE OF REVIEW: Community-acquired pneumonia (CAP) is associated with significant morbidity and mortality and is the most common cause of death from infectious diseases. CAP patients requiring intensive care unit (ICU) admission carry the highest mortality rates. This paper aims to review the current literature regarding epidemiology, risk factors, severity criteria and reasons for admitting the hospitalized patient to the ICU, and the empiric and specific antibiotic therapeutic regimens employed. RECENT
FINDINGS: Multiple sets of clinical practice guidelines have been published in the past few years addressing the treatment of CAP. The guidelines all agree that CAP patients admitted to the hospital represent a major concern, and appropriate empiric therapy should be instituted to improve clinical outcomes.
SUMMARY: The cost, morbidity and mortality of CAP patients requiring ICU admission remain unacceptably high. These are heterogeneous groups of patients, so it is important to use risk-stratification based on clinical parameters and prediction tools. Appropriate antibiotic therapy is an important component in the management of both groups of patients. In particular, it is essential to administer an appropriate antimicrobial agent from the initiation of therapy, so that the risks of treatment failure and the morbidity of CAP may be minimized.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17075331     DOI: 10.1097/QCO.0b013e3280106b7f

Source DB:  PubMed          Journal:  Curr Opin Infect Dis        ISSN: 0951-7375            Impact factor:   4.915


  4 in total

1.  Bacterial community-acquired pneumonia: risk factors for mortality and supportive therapies.

Authors:  H Lode
Journal:  Intensive Care Med       Date:  2008-12-10       Impact factor: 17.440

2.  Mortality in ICU patients with bacterial community-acquired pneumonia: when antibiotics are not enough.

Authors:  Alejandro Rodriguez; Thiago Lisboa; Stijn Blot; Ignacio Martin-Loeches; Jorge Solé-Violan; Diego De Mendoza; Jordi Rello
Journal:  Intensive Care Med       Date:  2008-12-10       Impact factor: 17.440

3.  Patient Outcomes on Day 4 of Intravenous Antibiotic Therapy in Non-Intensive Care Unit Hospitalized Adults With Community-Acquired Bacterial Pneumonia.

Authors:  Scott B Robinson; Frank R Ernst; Craig Lipkin; Xingyue Huang
Journal:  Infect Dis Clin Pract (Baltim Md)       Date:  2014-11

Review 4.  The role of biomarkers in community-acquired pneumonia: predicting mortality and response to adjunctive therapy.

Authors:  Jean-Paul Mira; Adeline Max; Pierre-Regis Burgel
Journal:  Crit Care       Date:  2008-11-26       Impact factor: 9.097

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.